Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
about
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyMedical treatment of early stage and rare histological variants of epithelial ovarian cancerOlaparib in the management of ovarian cancerA phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group studyGenes associated with histopathologic features of triple negative breast tumors predict molecular subtypes."Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsDelivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy.Single-sample expression-based chemo-sensitivity score improves survival associations independently from genomic mutations for ovarian cancer PatientsPARP Inhibitors in Reproductive System Cancers: Current Use and Developments.Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literature.Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.Advances in the recognition and management of hereditary cancer.PARP inhibitors as antitumor agents: a patent update (2013-2015).The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.Prediction of therapy response in ovarian cancer: Where are we now?Germline Mutations in Triple-Negative Breast Cancer.Discovery of mutations in homologous recombination genes in African-American women with breast cancer.The more you look, the more you will find.Cancer Genetic Counseling and Testing: Perspectives of Epithelial Ovarian Cancer Patients and Gynecologic Oncology Healthcare Providers.Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).Update Breast Cancer 2017 - Implementation of Novel Therapies.Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.Recombination rate plasticity: revealing mechanisms by design.Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer.Olaparib in Epithelial Ovarian Cancer.Pathway-based dissection of the genomic heterogeneity of cancer hallmarks' acquisition with SLAPenrich.Association of with early age onset of breast cancer patients in selected cohort from Pakistani populationSpatiotemporal dynamics of homologous recombination repair at single collapsed replication forksThe efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials
P2860
Q26769604-D4260526-7053-4425-A2DC-181A8C4521D7Q26777702-9EEC7A1F-65D5-4DBA-911F-93D3DAB45CFDQ26797166-F10EEB57-BADF-491C-8F6A-C311FECA16F5Q30277998-63A6D640-E7C5-46ED-B87D-73E02CF5FE95Q33589487-B942B646-2441-4261-A5F6-833CD92C045DQ33618910-CB3FA946-FCF4-4038-B3CD-C9C81570B005Q36257738-E63172FB-52EB-439D-A7E0-D99BD5A936DDQ37211342-1BFB859A-5155-4A0E-A7F5-3290DBA5E35EQ37607283-2E2FAD96-D6C2-4826-8205-4230D52851E7Q37661436-10FD6772-A54B-43A5-868F-F569511DC3CDQ38373098-70463547-8E0F-4EAD-83F2-5C26B6250E60Q38375045-107BDBD1-8CAC-44DC-A088-9A69850F7410Q38795712-A457F5F9-D46A-416D-8151-AAB5D96818DEQ38817846-AA503D2E-75F0-4179-A21B-60E10E3CE053Q38852352-38C5C5ED-F92C-4A5D-9BAD-7777FC8A228DQ39263260-8D1DFACF-069A-46F5-84DF-095CE39658D3Q39370774-124DD482-6C1C-4FAD-8294-BF12B4A142FFQ40060771-459BD3D3-E8C1-4418-9B5B-8F7108D5F123Q44668262-1E3FEB15-5096-45BD-956A-76AF4F0C614CQ46109910-44B0FF2B-81EE-43EA-A63E-C4C8130A5643Q46567658-C1A222CF-C125-449E-B57D-09C17197A441Q47110841-F0C15716-AD38-4BF0-911F-A98AF2F9B5A7Q48118236-21D6CB34-D5E4-4BA1-9FF0-80558DEC4B3AQ50448934-0264A28C-13F3-4AEF-A846-8D25995B3EB5Q54877659-E8AF0B8D-02CC-49E2-A58D-381B2529F7CDQ55002468-202F4E6A-04ED-41FD-8ADF-78FB6C89C32EQ55080794-7D31DF88-8986-4377-AA9B-40FDBDCEB742Q57822999-E3BD6353-0E6A-40C7-9F77-688490255A96Q58700573-910A4668-7E5E-477C-98DB-819BED4A3B3DQ58790609-376FD42A-1EBA-4CAE-97CB-56648624935B
P2860
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@ast
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@en
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@nl
type
label
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@ast
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@en
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@nl
prefLabel
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@ast
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@en
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@nl
P1433
P1476
Two decades beyond BRCA1/2: Ho ...... get for ovarian cancer therapy
@en
P2093
Christine S. Walsh
P304
P356
10.1016/J.YGYNO.2015.02.017
P407
P577
2015-05-01T00:00:00Z